This study is looking at a combination of two drugs, pembrolizumab and lenvatinib, for women with advanced cervical cancer that has progressed or not responded to at least one previous treatment. Pembrolizumab is given through an IV every three weeks, and lenvatinib is taken daily by mouth. The study aims to see how many patients respond to this combination therapy, specifically if their tumors shrink or disappear. Researchers believe this combination might help the body's immune system fight the cancer better. You may be able to join if you are at least 18 years old and have locally advanced or metastatic (spread) cervical cancer that has not responded to previous treatment. The study plans to enroll up to 35 participants.

Study design

This is a Phase 2 interventional study, meaning all participants will receive the study drugs. It will enroll up to 35 participants in a two-stage design.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The primary outcome, Objective Response Rate, will be measured for up to 2 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.